<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPTR022154</article-id>
      <title-group>
        <article-title>Design and In-Vitro evaluation of human serum albumin loaded Paclitaxel nanosuspension</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ganji</surname>
            <given-names>AmarnathReddy</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jadhav</surname>
            <given-names>Kiran K</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Umachigi</surname>
            <given-names>Sanjay P</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shivakumar</surname>
            <given-names>Pradeep</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>SainathReddy</surname>
            <given-names>Palleti</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Anilchowdary</surname>
            <given-names>Yedla</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Gautham College of Pharmacy, Department of Pharmaceutics, Bangalore, India.</aff>
      <aff id="aff2">Lamar University, Department of Chemistry, Beaumont, Texas, U.S.A.</aff>
      <pub-date pub-type="epub" iso-8601-date="2012-04-01">
        <month>04</month>
        <day>01</day>
        <year>2012</year>
      </pub-date>
      <volume>2</volume>
      <issue>2</issue>
      <abstract>
        <p>At current 40% of the drugs were poorly soluble and were also called as “brick dust”. And the drugs which were belonging to the BCS CLASS II &amp; IV were most eligible for this Nanosuspension technology. Here by using different methods we are reducing the particle size so the surface area will be increases ultimately it leads to increase in the bio availability. This instance was observed mostly in the case of anti-cancer drugs. Paclitaxel with 25% of Human Serum Albumin (HSA) showed very good results in terms of drug content, particle size, zeta potential and %CDR. Key words: Nanosuspension, Paclitaxel, Human Serum Albumin (HSA), High pressure homogenization.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Nanosuspension</kwd>
        <kwd>Paclitaxel</kwd>
        <kwd>Human Serum Albumin (HSA)</kwd>
        <kwd>High pressure homogenization.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
